Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,845 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Autoimmune / Connective Tissue Diseases Clear all

Conditions: Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus
Interventions: BIIB059 (litifilimab), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 53
States / cities: Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more

Conditions: Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
Interventions: Descartes-08; Drug
Lead sponsor: Cartesian Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • St Louis, Missouri • Cincinnati, Ohio

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more

Conditions: Granulomatosis With Polyangiitis
Interventions: Airway assessment, Rheumatology assessment; Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Systemic Lupus Erythematosus
Interventions: DZP, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 16 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Juvenile Psoriatic Arthritis
Interventions: Secukinumab; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: Loma Linda, California • Gainesville, Florida • Chicago, Illinois + 8 more

Conditions: Rheumatoid Arthritis, Degenerative Arthritis, Post Traumatic Arthritis
Interventions: Integra Cadence Total Ankle System; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Sarasota, Florida • Buffalo, New York + 5 more

Conditions: Non-infectious Uveitis
Interventions: AIN457, AIN 457; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 20
States / cities: Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more

Conditions: Musculoskeletal Diseases
Interventions: Multimedia Patient Decision Aids (MM-PtDAs), Comparative Effectiveness Research Summary Guide (CERSG), Questionnaires; Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 676 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Arthritis, Rheumatoid, Vitamin D Deficiency
Interventions: Placebo in arm A and Vitamin D in arm B, vitamin D 3 for arm A ,and matching placebo for arm B; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Arthritis, Rheumatoid
Interventions: Tai Chi Chih, Relaxation training; Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Arthritis, Rheumatoid
Interventions: CP-690,550, placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 33
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Upland, California + 26 more

Conditions: Systemic Lupus Erythematosus
Interventions: Mycophenolate Mofetil, Placebo for Mycophenolate Mofetil, Voclosporin, Placebo for Voclosporin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 6 more

Conditions: Rheumatoid Arthritis
Interventions: JNJ-38518168, Placebo, Methotrexate; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: SLE (Systemic Lupus)
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Systemic Lupus Erythematosus
Interventions: CEP-33457; Drug
Lead sponsor: Cephalon, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 39
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 33 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions: Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab; Drug
Lead sponsor: Jeffrey Curtis; Other
Eligibility: 18 Years to 85 Years
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: Subcutaneous (SC) Abatacept, Intravenous (IV) Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 2,492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 70
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 63 more

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib disodium (R935788), Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: La Jolla, California • Palm Desert, California • Hamden, Connecticut + 21 more

Conditions: Lupus Nephritis (LN)
Interventions: Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis Shoulder, Rheumatoid Arthritis, Oncology
Interventions: Not listed
Lead sponsor: Exactech; Industry
Eligibility: 21 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Lymphoma
Interventions: No intervention; Other
Lead sponsor: Centocor Ortho Biotech Services, L.L.C.; Industry
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 3
States / cities: Highland Park, Illinois • Wichita, Kansas • Albany, New York

Conditions: Rheumatoid Arthritis
Interventions: Natrunix, Placebo; Drug
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 26
States / cities: Covina, California • Encino, California • Rancho Mirage, California + 19 more

Conditions: Rheumatoid Arthritis
Interventions: Tofacitinib, Abatacept; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 29,464 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

Clinical Evaluation of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement (CADENCE)

Safety and Efficacy of AIN457 in Noninfectious Uveitis

IADAPT-Third Phase

Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis

Comparing Tai Chi Chih and Relaxation Therapy in the Treatment of Rheumatoid Arthritis

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)

A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus

COVID-19 VaccinE Response in Rheumatology Patients

Methotrexate-Inadequate Response Study

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

Dapagliflozin in Active Lupus Nephritis

Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)

An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.

Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept